Distributed Bio must have a big name backer becaus
Post# of 155256
(Total Views: 453)
Posted On: 04/04/2020 10:22:12 AM
Distributed Bio must have a big name backer because their about a decade or more behind leronlimab. They literally just manufactured their antibody in the past month or two and haven’t even collected preclinical or a phase 1 for safety. To think the FDA would give them compassionate use for COVID19 in the next 6 months is an insane idea.
Oh, they’re also “crowd funding” to raise money. I respect their drive and enthusiasm, and the ability of their small company to get on Fox News, but the COVID19 pandemic will have passed and a vaccine will be nearly complete by the time their anti-body is even tested in a sick patient, of ever.
Note in the excerpt from their website below that they have a, “panel of antibodies,” which means they haven’t even identified the most likely antibody yet.
“Since January 25, 2020, a group of Distributed Bio employees has worked tirelessly to engineer a treatment for the novel COVID-19 coronavirus. When San Francisco and then California issued a shelter-in-place ordinance, our team members volunteered to brave the pandemic, worked in shifts on nights and weekends to complete the medicine.
Our strategy was to engineer a panel of anti-SARS antibodies to make them recognize and block the novel coronavirus. The result of that work is a panel of ultra-high affinity therapeutic antibodies to neutralize SARS-CoV-2 (the virus behind COVID-19).”
Oh, they’re also “crowd funding” to raise money. I respect their drive and enthusiasm, and the ability of their small company to get on Fox News, but the COVID19 pandemic will have passed and a vaccine will be nearly complete by the time their anti-body is even tested in a sick patient, of ever.
Note in the excerpt from their website below that they have a, “panel of antibodies,” which means they haven’t even identified the most likely antibody yet.
“Since January 25, 2020, a group of Distributed Bio employees has worked tirelessly to engineer a treatment for the novel COVID-19 coronavirus. When San Francisco and then California issued a shelter-in-place ordinance, our team members volunteered to brave the pandemic, worked in shifts on nights and weekends to complete the medicine.
Our strategy was to engineer a panel of anti-SARS antibodies to make them recognize and block the novel coronavirus. The result of that work is a panel of ultra-high affinity therapeutic antibodies to neutralize SARS-CoV-2 (the virus behind COVID-19).”
(1)
(0)